Pollution in Delhi peaks in late autumn when drifting emissions from crop burning exacerbate the usual urban household, traffic and industrial sources

India’s air quality data, removed at the last minute from the WHO Air Quality database update just prior to its launch two weeks ago, has been restored again to the online repository

The omission of data from dozens of cities in one of the world’s most polluted nations went unnoticed by major media until it was reported last week by Health Policy Watch.

At the time, WHO sources denied that any pressure had been applied by the Indian government to suppress or alter the data.  Rather, the India data was deleted from the online database so as to perform a final data check that was somehow overlooked in the lead-up to the launch. 

“The World Health Organization, after a thorough review, have now included the Indian cities, and have taken immediate steps to update this on its WHO web site, and in the database,” a senior WHO scientist told Health Policy Watch

WHO’s belated inclusion of Indian cities to its 2022 update covering air quality in 6,000 cities and settlements around the world, was noted Tuesday by Indian media and air quality advocates:

“Indian cities have finally been added by @WHO to its latest #airpollution report. Nine of the top 15 most polluted places are in India in the last 3 years,” tweeted Chetan Bhattacharji, senior managing editor at India’s NDTV station.  

“After several phone calls and emails, the mystery remains unsolved, but at least the data is back,” said the non-profit group Care for Air. “Data transparency is data democracy. And transparency precedes awareness and action.”  

The data still reveals a glum national situation for India. Although Lahore, Pakistan; Kabul, Afghanistan and Hetian Shi, China rank as the three most polluted cities in the world, they are closely followed by eight Indian urban centres – Delhi included.  

Air Pollution value for Delhi unchanged, but some others reflect refinements  

PM2.5 values for Delhi and a number of other major cities were largely unchanged in the final, published WHO data set, as compared to the embargoed version of the data, which was dropped at the last minute from the WHO 2022 database launch on 4 April, but published by Health Policy Watch last week. 

Comparisons of values for major Indian cities in the 31 March, embargoed WHO database and the final dataset released on 19 April. (Health Policy Watch compilation from WHO datasets)

The now updated Indian dataset does include other significant technical refinements. For instance, data for large Indian cities from the Indian government’s Central Pollution Control Board (CPCB), the statutory authority responsible for monitoring air quality is now incorporated more fully.  

Previously, data for Delhi and a number of other large Indian cities had been attributed only to the US AirNow programme, which monitors air quality from its missions and embassies around the world – but is not an official government data source. 

In a few cases, the final inclusion of the CPCB data actually led WHO to report on higher pollution values.  

For instance, in Agra, the annual average of PM 2.5 air pollution concentrations for 2019 was 109.67 µg/m3 – about 17% higher than the 91 µg/m3 value included in the embargoed dataset. The final data also includes more CPCB monitoring points – covering some 85% of the city. 

Other corrections included the elimination of duplication in the Indian names Bangalore (British spelling) and Bengaluru (Indian) – with the British spelling chosen as the reference. Data from Haryana, the Indian state that surrounds Delhi on three sides, was deleted. While that is presumably because Haryana is a state and not a city, that reduces valuable perspective of air quality in a strategically important farm area – where smoke from rice stalk burning drives heavy pollution into Delhi in the late autumn. 

WHO-led BreatheLife campaign site offers an interactive search experience for air pollution data from cities globally. Here, results  for Delhi – along with estimated deaths/year in India from air pollution.

WHO database ‘not designed to derive trends’ in developing cities over time  

Although WHO’s air quality database was a bold move for the global health agency when it was first established over a decade ago – one significant limitation of WHO’s urban air pollution reporting today is the lack of analysis of trends in major cities over time.  WHO produces no such analysis for cities – even though more than a decade’s worth of ground station monitoring data is now available. 

“The WHO database has never been intended to derive trends,” in the cities that it tracks over time, the WHO scientist told Health Policy Watch

“Even with the historical data that is included, it is difficult to do such type of analyses for many reasons (based on the same limitations highlighted for intercity comparisons).” 

Nonetheless, other global experts are indeed looking at trends at national and urban level – and particularly in large cities seen as drivers of change, both good and bad. 

One example is a paper on trends in developing country megacities, published on 8 April in Science AdvancesIt concluded that rising air pollution levels are driving a rise in air pollution-related mortality in African and South Asian megacities – where policymaker action on polluting vehicles, urban sprawl, home and power plant emissions – has been slow, if it happens at all.  

That analysis, which also references satellite sources, notes that observations of Aerosol Optical Depth (AOD) values reflect growing PM2.5 pollution in South Asian cities over the past decade. AOD is the level at which aerosols prevent light traveling through the atmosphere and is thus an indicator of PM2.5 concentrations. 

“Trends in AOD from 2005 to 2018 in South Asian cities are steep (2.5 to 7.8% a−1) and significant. AOD more than doubles in Bangalore (7.8% a−1) and Hyderabad (7.3% a−1),” report the authors from University College London, Harvard School of Public Health, the University of Birmingham and University of Brussels.  

“Earlier studies have reported similar positive trends for these cities, so our contemporary record supports sustained rapid growth in AOD (and thus PM2.5),” the authors say, adding that: 

“Desert dust likely does not contribute to trends in AOD over South Asian cities, as desert dust optical depth has declined over the Thar Desert and makes a negligible contribution to AOD trends across the rest of India.”  

Increase in premature deaths due to increase in exposure to PM2.5 in rapidly growing tropical cities. Bars give the increase in premature mortality in 2018 relative to 2005 for the top 15 cities, colored by the percentage point change in fraction of premature deaths attributable to exposure to PM2.5. Inset value is the total for the cities in Fig. 1 with detectable trends in AOD. (Science Advances)

Politicians in Asia and Africa also have often tried to blame high air pollution levels on either natural dust or biomass burning, related to household cooking, charcoal production or wildfires. 

However, the Science Advances article draws out multiple lines of evidence suggesting that other “anthropogenic” sources from vehicles, energy production and industry represent a growing piece of the pollution puzzle.

Notably, six African cities including Abuja, Ibadan and Conakry Nigeria, have exhibited “very steep increases in anthropogenic activity NO2” the authors note, referring to another health-harmful air pollutant, nitrogen dioxide closely associated with vehicle emissions. NO2 levels are rising at time when biomass burning, a traditionally prominent source of air pollution in Africa, is on the decline, the authors note.    

WHO planning global trends analysis update 

Along with avoiding trend analysis, WHO has discouraged using the data to make comparisons between cities – saying it’s main message is to encourage better monitoring altogether.

While it’s true that considerable technical inconsistencies in monitoring methods can make inter-city comparisons challenging, critics say that the real bigger barrier is political. As a member-state body, studies that lead to unflattering comparisons between member states puts WHO in an extraordinarily uncomfortable position.

WHO has in the past undertaken trend analyses – but with a focus more at the global or global and regional level. The latest such WHO paper, a hybrid analysis of both ground station monitoring and satellite data from 2010-2016, was published in Nature in 2020. It found that one-half of the world’s population are being exposed to increasing levels of air pollution. 

(Nature 2020) Graphic a: Average annual PM2.5 (μg/m3) Concentrations in 2016. b: Changes in PM2.5  concentrations 2010-2016 show South East Asia and Africa with the most rapid increases (in pink and red).

“We intend to publish an update of it, with the 2020 data early next year,” said the WHO scientist involved in the previous paper.  

In addition, the scientist added: “WHO has recently established a Global Air Pollution and Health Technical Advisory Group (TAG) which brings together over eighty of the top experts on the health and air pollution, working to better quantify the health risk from air pollution, and to provide guidance on quantifying the costs and benefits of different interventions to tackle air pollution, among other [tasks]. 

“The TAG will advise and support WHO on the relevant analysis and trends to be developed.”

See the exclusive Health Policy Watch analysis of the database here:

EXCLUSIVE: WHO Deleted India’s Air Pollution Data from its New Air Quality Database – Why? 

 

 

Image Credits: Flickr, Compiled by Health Policy Watch from WHO data , Science Advances, April 2022 , Nature (2020).

Airline easyJet had to cancel hundreds of flights as a result of a rise in COVID-19 cases in staff. It abandoned mask-wearing last month.

The Biden administration will no longer enforce its mask mandate for travel after a federal judge in Florida struck down the US Centers for Disease Control and Prevention (CDC) mandate for planes, buses and trains Monday afternoon. 

US District Court Judge Kathryn Kimball Mizelle ruled in favor of the Health Freedom Defense Fund which had initiated a lawsuit against the federal government in July 2021, stating that the mandate has “exceeded the CDC statutory authority.”  

“It is indisputable that the public has a strong interest in combating the spread of COVID,” Mizelle wrote

However, Mizelle also controversially claimed in her ruling that “wearing a mask cleans nothing” and that “at most, it traps virus droplets. But it neither ‘sanitizes’ the person wearing the mask nor ‘sanitizes’ the conveyance.”

The World Health Organization (WHO) recommends wearing a mask “as part of a comprehensive strategy of measures to suppress transmission and save lives”.

She ruled that the mask mandate exceeded the CDC’s statutory authority, declaring it unlawful as the CDC failed to explain its reasoning for the mandate.

“Because our system does not permit agencies to act unlawfully even in the pursuit of desirable ends, the court declares unlawful and vacates the mask mandate,” Mizelle ruled.

White House press secretary Jen Psaki had called the ruling “disappointing” at a White House briefing, citing the recommendation by the CDC to continue wearing masks in public transit.

“What we announced last week was just a two-week extension in order to have time to assess what we’ve all seen is rising cases, and make an assessment and recommendation with that in mind.” 

The federal ruling was initially set to expire on 3 May to allow more time to study the COVID-19 BA.2 Omicron subvariant now responsible for the vast majority of US cases. 

The US Department of Homeland Security (DHS), which would be implementing this ruling, and CDC are currently reviewing the decision. 

US airlines make masks optional

mask
Hartsfield–Jackson Atlanta International Airport in Georgia, US. Airlines across the country have opted to make masks optional following Florida ruling.

This ruling has quickly reshaped US air travel, as numerous carriers – Delta, United, Southwest, American, and others – have now said that masks are optional for travelers aboard aircraft. 

The massive shift means that airline employees also no longer have to wear masks and won’t have to enforce the rule on passengers. However, airlines also warn that travelers should still bring masks on trips to conform with the rules for where they land, especially for international flights. 

“To mask or not to mask, the choice is yours,” said Frontier Airlines on Twitter

While masks may be optional onboard, airlines such as Delta have warned that masks may be “inconsistently enforced” as the news is being “broadly communicated” over the next 24 hours.  

“Communications to customers and in-airport signage and announcements will be updated to share that masking is now optional – this may take a short period of time.” 

Delta had expressed optimism about the ruling, adding, “We are relieved to see the US mask mandate lift to facilitate global travel as COVID-19 has transitioned to an ordinary seasonal virus.” 

Other airlines have noted that they will be ready to respond to future COVID surges, should the need arise.  

“We are confident we will be ready to respond if faced with another COVID wave or even a new virus,” said Alaska Airlines.  

International airlines face canceled flights amid rising cases  

While airlines and passengers across the US are celebrating the end of mask mandates on flights, international flights have seen COVID-19 cases rise and flights cancelled following the removal of masks a month earlier.

More than 200 flights were cancelled by budget-friendly Swiss airline easyJet over the weekend, and more than 60 flights on Monday, with the airline blaming the cancellations on staff shortages caused by COVID-19. 

An easyJet spokesperson said: “As a result of the current high rates of COVID infectious across Europe, like all businesses, easyJet is experiencing higher than usual levels of employee sickness.” 

“We have taken action to mitigate this through the rostering of additional standby crew this weekend, however, with the current levels of sickness, we have also decided to make some cancellations in advance which were focused on consolidating flights where we have multiple frequencies so customers have more options to rebook their travel, often on the same day.

EasyJet made the move to not require masks on flights earlier in March, following the United Kingdom’s removal of all travel restrictions earlier in March

British Airways has also cancelled a small number of flights due to staff sicknesses during the Easter holiday weekend. 

Image Credits: Ben Queenborough/PinPep )F;oclr_, risingthermals/flickr.

A destroyed tank is abandoned on the road to Bucha, Ukraine.

Getting medical supplies and equipment to those Ukrainians who need it as fighting intensifies is one of the World Health Organization’s (WHO) biggest concerns, according to WHO Europe spokesperson, Bhanu Bhatnagar on Tuesday.

“An increase in fighting could further threaten our supply chains in and out of affected areas.,” said Bhatnagar, who is currently in Lviv, a Ukrainian town near the Polish border.

“To mitigate this risk, we plan to ramp up our donations to the Ministry of Health, assess the possibility of pre-positioning supplies in additional locations to help build a network of warehouses, for example in Poltava to serve the north and east, and Odessa to serve the south,” he added.

WHO has so far delivered 218 metric tonnes of emergency and medical supplies and equipment to Ukraine. Of that amount, 142 metric tonnes – roughly two-thirds – have reached their intended destinations, mostly in the east and north of the country where the need is greatest.

The WHO has a large storage facility in Lviv, some 65km from the Polish border, but the town – which had been a refuge for those fleeing fighting elsewhere – was targeted by Russian missiles on Monday, and may no longer offer a safe place for WHO supplies.

Generators and oxygen

The global body is also trying to get 15 generators delivered to hospitals across Ukraine this week, including to Mariupol, Kharkiv, and Luhansk and Donetsk oblasts but will only do so “when we can ensure the safety of our personnel and the precious cargo they are transporting”, said Bhatnagar.

“Patient care is heavily dependent on access to reliable power supply. Even a momentary power failure can have serious consequences for patients, for example, those needing medical oxygen,” he added.

In addition, only 10 oxygen plants are still able to supply hospitals and health services, and WHO is working on contingency plans with the Ministry of Health to address any disruptions.  

To date, the WHO has verified 147 incidents of attacks on health care in Ukraine, in which at least 73 people have died and 52 have been injured. Of these, 132 attacks have been on health facilities and 16 on ambulances.

Rape survivor training

WHO Europe has also been providing technical support to Ukraine to assist it to align its clinical protocols on health services for survivors of sexual violence with WHO guidelines and developing training curricula for primary health care providers on the clinical management of rape in humanitarian settings, according to its latest situation report.

This comes amid numerous reports of systemic rape of Ukrainian women and children by Russian soldiers.

The Executive Director for UN Women, Sima Bahous, told a recent UN Security Council briefing that the increasing reports of sexual violence and human trafficking in Ukraine — allegedly committed against women and children in the context of massive displacement and ongoing fighting — are raising “all the red flags” about a potential protection crisis.

Warning that “this trauma risks destroying a generation”, Bahous added that women make up 80% of all health and social care workers in Ukraine, and many have chosen not to flee as they want to help their communities.

The WHO has also hosted a webinar for pulmonologists in Poland to increase awareness and update them on the treatment approaches in Ukraine, especially on drug-resistant tuberculosis (TB).

Meanwhile, a case of highly contagious bacterial infection, diphtheria, has been confimed in  Donetsk oblast. 

Image Credits: Marco Frattini/ World Food Program.

There have been isolated case reports of SARS-CoV2-induced hepatitis in adults. Displayed here is a liver sample from a 34-year old SARS-CoV2 infected man displaying mild hepatitis inflammation, from a report published in May, 2021.

The World Health Organization has reported that it is investigating some 74 cases of acute childhood hepatitis, of an unknown origin, in the United Kingdom along with five suspected and confirmed cases in the Republic of Ireland.

That follows on previous reports of similar, severe hepatitis cases of an unknown origin among a cluster of nine children in the United States, as well as three children in Spain.

Oddly enough, WHO’s first “Disease Outbreak News (DON)” announcement of the mysterious hepatitis outbreak, which is puzzling scientists and healthcare providers, did not make any mention of the US cases already under investigation by the US Centers for Disease Control.

Altogether, some 91 children in the USA and Europe have now been reported to be confirmed or suspected ill, with the mysterious, and potentially deadly disease, since January.

That includes nine children in Alabama, 3 in Spain, and at least 74 in England, Scotland and Northern Ireland, according to a report from the University of Minnesota’s, Center for Infectious Disease Research and Policy (CIDRAP). Another five cases, confirmed or possible, have been reported in the Republic of Ireland, WHO also said on Friday.

The acute infections appear to be mostly associated with circulating adenoviruses – the viruses responsible for the common cold – rather than known hepatitis virus strains, US investigators have said.  But SARS-CoV2 has also been detected in several cases, WHO noted in its DON.

“Laboratory testing has excluded hepatitis type A, B, C, and E viruses (and D where applicable) in these cases,” the WHO said.  It added, however, that “Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) and/or adenovirus have been detected in several cases,” the WHO said.

“The United Kingdom has recently observed an increase in adenovirus activity, which is co-circulating with SARS-CoV-2, though the role of these viruses in the pathogenesis (mechanism by which disease develops) is not yet clear,” WHO added.

“Following the notification from the UK, less than five cases (confirmed or possible) have been reported in Ireland, further investigations into these are ongoing. Additionally, three confirmed cases of acute hepatitis of unknown aetiology have been reported in children (age range 22-month-old to 13-year-old) in Spain. The national authorities are currently investigating these cases,” WHO added. It made no mention, however, of the outbreak in the USA.

According to the WHO report, children present to healthcare providers with markedly elevated liver enzymes, often with jaundice, and they sometimes have gastrointestinal symptoms, including vomiting. At least 6 of the 74 UK patients required liver transplants.  So far no deaths have been reported.

The US CDC has said that it is working with Alabama on its investigation into the cases, as well as with other state health departments to see if there are cases elsewhere.

In a separate statement, The Alabama Department of Public Health, said that it had been investigating the increase in hepatitis cases in young children since November 2021.

“These children presented to providers in different areas of Alabama with symptoms of a gastrointestinal illness and varying degrees of liver injury including liver failure. Later analyses have revealed a possible association of this hepatitis with Adenovirus 41.

“To date, nine children less than 10 years old have been identified as positive for adenovirus and two have required liver transplants. The affected children were from throughout the state of Alabama, and an epidemiological linkage among them has not been determined. None of these children has had any underlying health conditions of note.”

There have been isolated case reports of acute hepatitis developing in SARS-CoV2 in young, and previously healthy adult patients. Some degree of liver injury has also been described among people hospitalized for severe COVID-19.

See the full WHO Disease Outbreak News report here.

Image Credits: F1000research.com.

The latest study on the effectiveness of a second COVID-19 booster, published last week in the New England Journal of Medicine, has shown that within a period of two weeks to one month after receiving the jab, recipients’ infection rates dropped by one-half and severe cases and deaths by three-quarters.

The study, conducted by Israel’s Clalit Research Institute in collaboration with researchers at Harvard University in Boston, is also one of the largest studies of the fourth jab to date – analysing data of more than 364,244 individuals -182,122 who received the second booster and the same number who did not.

The study also was conducted between January 3 and February 18, during the height of Israel’s Omicron wave – pointing to the continued effectiveness of at least the Pfizer mRNA COVID vaccine against that new, and more infectious variant.

“The results of the study can help each person make an informed decision about the need for a vaccine according to personal risk,” said Prof. Ran Balicer, Chief Innovation Officer for Clalit Health Services.

“Currently, one of the main reasons for hesitation regarding receiving the fourth vaccine dose is a lack of information regarding its effectiveness,” added Prof. Ben Rice, head of a predictive medicine group at Boston’s Children Hospital and Harvard Medical School. “The careful epidemiological research presented before us provides reliable information regarding the effects of the vaccine.”

According to the results, those who received the second booster dose experienced a 52% reduction in all infections; a 61% reduction in symptomatic infection; 72% reduction in hospitalizations; a 64% reduction in severe disease; and a 76% reduction in deaths compared to those who had only been vaccinated with the third dose (first booster), at least four months earlier.

“A fourth dose of the BNT162b2 vaccine was effective in reducing the short-term risk of Covid-19–related outcomes among persons who had received a third dose at least 4 months earlier,” the study concluded.

Western countries push fourth dose for most vulnerable

A second booster is equivalent to the fourth shot for anyone who took a Pfizer or Moderna mRNA vaccine regimen. For those who received Johnson & Johnson, it means the third shot. Most countries recommend it four months or more after receiving the first booster.

In January, Israel became one of the first countries in the world to recommend a second booster for people over the age of 50 and immunosuppressed individuals. Since then, a handful of other countries – mostly in the Western world – have followed suit.

In March 2022, the US Food and Drug Administration authorised a second shot for its elderly (over 50) and vulnerable populations, which was soon after endorsed by the Centers for Disease Control and Prevention.

Germany has approved the fourth dose for people over the age of 60 and the United Kingdom recently advised the shot for people over the age of 75.

The European Centre for Disease Prevention and Control (ECDC) and European Medicine Agency’s COVID-19 task force said earlier this month that while it is “too early to consider using the fourth dose of mRNA COVID-19 vaccines in the general population,” they recommend the fourth dose for adults over 80 “after reviewing data on the higher risk of severe COVID-19 in this age group and the protection provided by a fourth dose.”

The ECDC and EMA also noted that there is ”no clear evidence in the EU that vaccine protection against severe disease is waning substantially in adults with normal immune systems aged 60 to 79 years and thus no clear evidence to support the immediate use of a fourth dose.” However, they said that a re-vaccination campaign could start as early as the fall.

“So far, no safety concerns have emerged from the studies on additional boosters,” they said.

Earlier studies show similar results

The Clalit study follows a handful of other reports on the fourth shot, all conducted in Israel, most of which have been peer-reviewed.

A study published earlier this month, also in the NEJM, looked at the rate of infection and severe illness in more than a million Israelis over the age of 60 who received a fourth dose. It found that the rate of COVID-19 infection was initially two times lower among those getting a second booster, than among those who had only received a third dose. Protection against infection, per se, appear to wane quickly, that study found. while protection against severe illness appeared more sustained. The new study, carried out within a longer time frame, reinforces those findings.

“Rates of confirmed SARS-CoV-2 infection and severe Covid-19 were lower after a fourth dose of BNT162b2 vaccine than after only three doses,” the study using Israeli Health Ministry data concluded. “Protection against confirmed infection appeared short-lived, whereas protection against severe illness did not wane during the study period.”

Fourth COVID Vaccine Jab Provides Little Extra Protection to Healthy Individuals – NEJM

Fewer benefits for younger individuals

A separate study by researchers from Sheba Medical Center at Tel Hashomer, published only a few weeks earlier, focused on healthy healthcare workers. Significantly, that study, which also assessed the effectiveness of the fourth shot, found that it provides ““little protection, if any, from infection by COVID-19 among vaccinated young and healthy individuals in comparison to those vaccinated with only a third dose,” the lead researcher said.

That study included approximately 600 volunteers, among them 270 who received a fourth shot of either the Moderna or Pfizer vaccine. All of the volunteers had received three shots of the Pfizer vaccine prior to the trial.

Finally, a non-peer reviewed retrospective cohort study – this one also published in collaboration with Clalit Health Services – was published at the end of March. Of 563,465 members of the fund, 328,597 (58%) received a second-booster dose during the 40-day study period.

“Death due to COVID-19 occurred in 92 second-booster recipients and in 232 participants who received one booster dose,” the authors reported, translating to a 78% reduction in death compared to those who only received one booster.

“The main conclusion is that the second booster [fourth shot] is lifesaving,” Dr Ronen Arbel, Health Outcomes Researcher at Clalit Health Services and Sapir College, told Health Policy Watch.

Image Credits: Clalit Health Fund .

Nathalie Strub-Wourgaft, DNDi Director of COVID-19 Response & Pandemic Preparedness and coordinator of the ANTICOV consortium looking at COVID treatments in low-income settings. 

Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. 

The vision is of a common clinical-trial archives – which would store clinical trial research data on emerging and neglected disease threats – so that other researchers could draw on the primary data to examine new research questions as they emerge. 

The issue, which is also the focus of a draft World Health Assembly resolution sponsored by the United Kingdom, will be the focus of a special DNDi-coordinated panel session of the Geneva Health Forum, which meets 3-5 May in Geneva for its 2022 edition

The session, entitled “Data-Sharing in the Time of COVID: What Works and What We Need” features Strub-Wourgaft, who is coordinating DNDi’s ANTICOV Consortium of multi-country clinical trials testing treatments in low-income settings; along with Rob Terry, of the TDR, Special Program for Research and Training in Tropical Diseases.

The session also includes Naomi Waithira, Head of Data Management, Mahidol Oxford Research Unit and Philippe Guérin, Director of the Infectious Diseases Data Observatory (IDDO), an independent platform for clinical trial data-sharing, housed at Oxford University, which is co-sponsoring the symposium. 

What is the problem? COVID outpatient studies as an example 

DNDi’s ANTICOV consortium is testing a range of outpatient COVID treatments suitable for low-income settings. But more systematic data-sharing of such clinical trial results is critical, particularly in a pandemic, in order to ensure rapid and robust recommendations, says Strub-Wourgaft.

The sad state of studies on outpatient treatments for COVID patients provides and illustration of the problem that Strub-Wourgaft aims to address, together with her other colleagues. 

“For outpatients, we’ve had thousands of studies that have looked at outpatient treatments,” said Strub-Wourgaft. “Many were underpowered” – meaning that they lacked enrollment of sufficient numbers of people to yield statistically significant results. 

Unlike hospital-based studies, which naturally have a large pool of patients to draw from, outpatient studies are often undertaken by independent working from smaller clinics, and enrolling a comparatively small sample size of patients. While such studies sometimes can provide proof of concept – they don’t usually yield the kinds of definitive results that can lead to national or global policy recommendations.

“So how do you make sense of this? We know many of the small-sized studies could not bring evidence to anything. Having a good system of data-sharing in place, however, would have helped a great deal.

She cites the big debate over the controversial treatment with ivermectin as one such example- where a plethora of small-scale studies led to conflicting results – and lots of debate – until very recently after results of a larger scale trial in Brazil were finally published

“It was studied all over the place, with all dose regimens” she points out, but the diversity of data only fueled the fires of controversy.  

Ivermectin – traditionally used against onchocerciasis, and a now-debunked COVID treatment.

The often bitter debate over efficacy could have been settled long ago with more conclusive evidence that the drug was not efficacious as a COVID treatment – had the smaller outpatient trials on mildly ill patients been linked up together systematically  –  with common methods, dose regimes, measurement and outcome standards at the individual patient level..  

To link disparate trials of any type of treatment,  “There needs to be analysis at individual patient level,” she points out. “This is where you get the best signals. It’s now being promoted [as an approach] but too late.” 

For instance, even the smallest discrepancies, such as the different formats that may be used for entering a patient’s date of birth – in the American style of 04-14-1990 as compared to the  European, Asian and African 14-04-1990, can befuddle attempts to rapidly compare clinical trial data from disparate studies very easily – and thus draw more robust conclusions about trial outcomes. And these delays can be deadly in a pandemic when rapid rollout of new treatments is all the more critical, Strub-Wourgaft points out.   

“Say that I want to look at the effect of age on a treatment’s efficacy,” said the DNDi scientist. “ If someone is entering the data on age with month-year, someone else with years, someone else day-month-year, how can you consolidate this.. There is a lot of work to be done so that you can pool this information.

“But for any new diseases that emerge in two years, this is something that we should be ready for.  We should have our data samples in the same format, so we can pull the data,” Strub-Wourgaft said.

Convincing researchers to share 

Clinical trial researcher examines sample.

But developing common templates for data collection for clinical trials of similar drugs or illnesses is almost the easy part of this quest by Strub-Wourgaft and like-minded colleagues.  

The even harder part will likely be convincing researchers from both academia as well as the for-profit pharma sector to share their results in a common platform – where potentially other researchers could pool data together, as well as drawing pre-existing  data results to examine new questions that emerge, such as the effects of a drug in pregnancy, or safety of a childhood dose. 

“There is a lot of work to be done so that you can pool information. It is so important, and sometimes very important signals will only come through the analysis of this pooled data… but it’s still a very relevant message,” Strub-Wourgaft says. 

“If not for ethical reasons, for scientific reasons we should share. For COVID, many people are agreeing we should have data sharing, but the devil is in the details, and those are not not in place.” 

And along with common trial protocols and templates, to really begin sharing, you need a data repository, where data can be stored – and shared under the appropriate, safe and confidential conditions sensitive patient data. 

IDDO – A platform for controlled data sharing  

IDDO, an Oxford University-hosted initiative linking the world of clinical trial data.

“Where could such a repository be?” she asks rhetorically.  “It needs to be in an independent unit. it needs to be fully equipped with the legal and technical infrastructure,” she says. 

DNDi, for its part,  found a solution in the Oxford-based IDDO, which initially had begun offering just such a repository for sharing of data on clinical trials about NTDs, but now is gradually expanding its reach to COVID treatments too.

She is hoping that DNDi’s example can inspire a broader dialogue and consensus over data sharing in a common repository – at least for NTD treatments and for any treatments that would tackle SARS-CoV2 still mutating variants, as well as other re-emerging or new, emerging pathogens that pose an outbreak threat. 

“Today, we are not asked to put anything anywhere,” she points out. But she hopes that status quo may change, under the new UK initiative in the WHA, supported by WHO, to create a common protocol for data sharing – at least in the case of publicly-funded trials. 

“In the clinical trials resolution being launched by the UK and WHO, we should say that data sharing is a must,” she declared. “The process to facilitate this should be put into place, and funding should be put into place. 

And in future research efforts supported by public institutions, researchers should agree to pool their clinical trial results as a condition of receiving their funding, she said. 

“The timing of this is sensitive, but I think there should be an agreement. Especially in the case of a pandemic, this is important. Having a sense of speed for a pandemic, it should be a kind of no-brainer.”

Addressing European data rules  

Under the IDDO platform, data is not entirely open at all.  In fact, the modalities of sharing are still carefully controlled. If one researcher wants to look at, and use, the data from the clinical trial of another research colleague or institution, then a request is filed via the platform, and the research institution that received the request can still respond with a yes or a no. 

Strub-Wourgaft stresses the importance that to be useful, such data needs to be shared at the individual patient level, what is called IPD data in the clinical trial world. 

Without precise data on a patient’s age, ethnicity, gender and other factors that can influence trial results, the kinds of more refined analyses that researchers often wish to conduct, become impossible. 

Arriving at that level of granularity in data-sharing creates other challenges, she admits, particularly with respect to new European data protection rules. 

“We are moving into a complicated situation with the European Global Data Protection Rules,” she observes. “Which provides that you will not put patients at risk, via the data that is shared.  

“There are growing concerns that we might have to  pseudo anonymise the data – because someone could still find out who a patient is, because of available data on data of birth, gender, age, place of location.

“Some push for very extreme interpretations of this.. Removing DOB altogether. But if you do that, then data sharing is really not of much use. That could make the data unusable. So the protection argument has to be nuanced. If Europe is too cautious about this, you might lose the value of the data.  

Pending WHA Resolution on Data-Sharing 

World Health Assembly Committee A in a past session: a proposed resolution to promoted sharing of harmonised clinical trial data is likely to be considered in the upcoming 75th session, May 22-28.

Strub-Wourgaft hopes that the pending WHA resolution, whose draft has not yet even been made public, might provide a framework that answers such questions. 

Should such a resolution be approved, it would also likely mandate WHO, as the world’s global health authority,  to “host” the technical data-sharing entity – whether that is IDDO or a consortium of such entities working together.

Strub-Wourgaft sees TDR, a WHO-based research entity, as the natural candidate  as the natural place to legally ‘host’ that repository.

“I would see this as being hosted by TDR, which is WHO and is doing research for WHO,” she says. 

Modalities of hosting by TDR

Robert Terry, Manager at TDR

TDR’s Terry is enthusiastic about the concept and direction: “Research funded by TDR shows that on average only 14% of registered clinical trials indicate they will be prepared to share the individual patient data (IPD) underlying a trial. 

“And there has also been no improvement in this figure when you look at pandemic diseases (including Ebola, Zika and Covid-19) despite  the various calls to share data from Wellcome Trust and partners and the WHO. 

He points to the recent TDR findings on this very topic, “Promotion of data sharing needs more than an emergency” published in the Wellcome Open Research Gateway. 

In terms of TDR’s own potential role in playing “host” to a global clinical trial data-sharing platform: 

“TDR has been involved in facilitating data sharing with the research communities it funds  for over 10 years including malaria, Schistosomiasis and other HATs.  And we have been working with IDDO to create the right governance processes for access particularly with regards to Ebola,” he adds, noting that TDR will also be publishing guidance on how to share data for its own staff and researchers in coming weeks.

In terms of the nuts-and-bolts infrastructure of such a repository, he said: 

“We felt it is better to support existing resources, particularly IDDO, rather than  to create our own [data repository] as there is a range of unique skills required to curate and provide access to data in ways that are effective, ethical and equitable. 

IDDO also is not alone in the field either, Terry adds, “There are many [other] types of platforms, including excellent resources such as the Data Compass at LSHTM. So TDR would rather establish principles of data-sharing and promote the use of these existing resources rather than fragment the sector further.

“We don’t believe the biggest barrier is infrastructure anymore.  It is a resistance to share among the research community, which needs to be addressed through better attribution of data sets (e.g. using a DOI to cite as a reference) and a change in academic assessment to recognise and reward data-sharing. 

“We are working with the Research Data Alliance, the European Union and the Global Health Network to keep getting the message across.” 

____________________________________________

See the complete GHF 2022 programme. Register here by 15 April for early bird fees: From 15 April to 2 May, fees are CHF 400 for the entire event and CHF 150 for participants from low- and middle income countries (OECD classification).  Daily rates are also available. 

Check out Health Policy Watch’s ongoing coverage of other themes featured at this year’s Forum on our GHF 2022 microsite:

Image Credits: DNDI/Twitter, Wellcome Trust , IDDO , WHO / Antoine Tardy, WHO/TDR.

Shanghai on 13 April registered 2,573 local COVID19 cases and 25,146 asymptomatic infections.
6,740 COVID19 patients were discharged from a makeshift hospital on 13 April.

China’s financial hub Shanghai continues to see rising COVID-19 cases despite the country’s attempts at a “no COVID” policy

The city reported over 27,000 coronavirus cases on Thursday, a new high, following Chinese President Xi Jinping’s announcement a day earlier reinforcing the zero-tolerance approach to COVID. 

“Prevention and control work cannot be relaxed,” Xi said during a trip to the island province of Hainan, the official Xinhua News Agency reported late Wednesday.

The policy has involved mass testing, long quarantines, and mostly closed borders. As of Monday, about 343 million people across 45 Chinese cities – accounting for 26% of China’s population and 40% of its economic output – were either under full or partial lockdowns, according to estimates by economists at the investment bank Nomura. 

But the wide curbs to stop the spread of the highly infectious Omicron variant have led to logistical and supply chain disruptions that are taking economic toll on the country and its people, especially in Shanghai. 

Makeshift quarantine centers test Shanghai’s patience 

shanghai
Shanghai’s current largest fangcang, or makeshift hospital, has set aside 900 beds to treat families with children under the age of 18 infected with COVID-19.

While China drums up support for its aggressive COVID strategies, Shanghai residents see their patience being tested amidst family separations and quarantine camps.

A video provided on Thursday to Reuters from inside one quarantine center showed people in camp beds separated by less than an arm’s length. An occupant has said that more than 200 people there shared four toilets, with no showers. 

Shanghai has converted multiple public venues to shelter hospitals – or fangcang – to house COVID-19 patients with mild or no symptoms. 

Children have also been attending online classes in these makeshift quarantine centers, as shown in a tweet from China state-affiliated media Sixth Tone. 

Once discharged, many former residents of these “shelter hospitals” have complained of difficulties ranging from post-recovery quarantine to securing food supplies to last the lockdown.

A Shanghai resident, last name Guo, told Sixth Tone that she waited for about four days to be transferred from a centralized quarantine facility to her home on Wednesday. 

“Medical staff told us we had met the criteria for being discharged, but had to wait for further notice, again and again … I grew anxious about testing positive again after hearing of a similar case,” Guo said. “Getting infected is actually nothing serious. But the chaos makes me feel exhausted.”

More than 20,000 recovered patients were released from six shelter hospitals managed by the city government over the past two days, authorities said Thursday.

According to China’s latest rules, those infected are allowed to be discharged from quarantine facilities or hospitals after they test negative for the virus in two consecutive tests, 24 hours apart. 

International community and local officials express concern for tightened measures 

Shanghai’s largest makeshift hospital, which can provides 50,000 beds, has been put into use to receive COVID-19 patients. The hospital was converted from the National Exhibition and Convention Center.

Shanghai’s lockdown has evoked a sharp response from the international community, as China stands in marked contrast with other parts of the world that are learning to live with the virus

Authorities had imposed a two-stage lockdown to encompass the entire city. 

“China is going to be left behind,” said Siva Yam, president of the Chicago-based U.S.-China Chamber of Commerce, to US-based media company Politico

“When you look at the United States and Europe, they are opening up, they have accepted the fact that the only way you can control [COVID] is to accept that it will [circulate] in the community.”

However, the Chinese government has continued to ramp up its “no COVID” messaging, with China’s official Xinhua news agency warning Thursday that the country’s medical system risked “breaking down” in the event of an even larger COVID outbreak. 

The state newspaper China Daily boasted last Saturday: “China to defeat Omicron again with dynamic zero-COVID policy” .

Officials and experts have expressed concern regarding tightening controls on the healthcare system, with one official close to China’s Center for Disease Control and Prevention telling British newspaper Financial Times that the “zero-COVID policy” is no longer viable.

“From a medical standpoint, I don’t think the zero-COVID policy is viable any more. Shanghai is running out of medical professionals to measure test results and beds to accommodate patients.”

Image Credits: yelingxuan369/Twitter, Zhang Meifang/Twitter, Yin Sura/Twitter.

South African President Cyril Ramaphosa visits the Aspen Pharmacare manufacturing facility.

Aspen, the South African based pharmaceutical company licensed to produce the Johnson & Johnson COVID-19 vaccine, has not yet received a single order from the African continent and might close its COVID vaccine production line.

This was disclosed by Dr John Nkengasong, director of the Africa Centre for Disease Control and Prevention, at a media briefing on Thursday at which he appealed to African countries, COVAX and Gavi to “rally around” Aspen to protect vaccine production on the continent.

It was “shortsighted” of African countries to rely on vaccine donations at the expense of the continent’s vaccine manufacturing capacity, Nkengasong told the briefing.

“There is a global consensus that, in order to ensure global health security, there must be regional vaccine manufacturing capacity. Here we are with a company that is producing an amazing vaccine that the continent is using that is running a risk of shutting down that production. We cannot and must not allow that to happen,” he stressed.

“If we only rely on donor vaccines and do not invest in and promote our own facilities on the continent that is a recipe for going backwards the next time we are hit with another pandemic.”

Africa has not cancelled orders

At a media briefing of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) on Wednesday, Pfizer CEO Dr Albert Bourla said that the US had been unable to donate 800 million Pfizer doses to Africa as the continent lacks the capacity to use them.

In addition, IFPMA Director General Thomas Cueni claimed that the Africa CDC, which coordinates much of the continent’s COVID-19 vaccine orders, had “stopped” and even “cancelled” orders because of African countries’ inability to roll out vaccination programmes.

However, Nkengasong said this was not the case. The continent had simply asked companies and donors to coordinate efforts to ensure that millions of doses are not delivered to the continent at the same time.

Huge volumes of doses have been lined up for delivery during the first quarter of the year, exposing African countries to the potential of having to dispose of expired stock if they could not get them out fast enough, he added. Kenya has, for example, recently destroyed 800,000 unused and expired vaccines.

“It is not because some parts of the world have now finished vaccinating and they have access that they donate in Africa that Africa will be ready to use all those vaccines at the same time,” said Nkengasong. “It must be coordinated, it must be done as a programme.”

He stressed that “even if you are a developed country and vaccines suddenly show up on your border in abundance, you run the risk of not using those vaccines appropriately”.

Nkengasong also appealed to the global community to invest the same energy it had in getting vaccines to ensuring that these “got into arms” by supporting the transport, storage, and human resources needed to vaccinate people, as well as accessories such as needles and syringes.

African Union launches youth vaccination drive

Nkengasong said that African countries should still aim to vaccinate 70% of their citizens by the third quarter of the year.

“We should not be deceived that because we are in a low transmission season in Africa and across the world that we will not see a pandemic rebound. We’ve seen this scenario over and over,” he stressed.

Africa CDC’s data showed a consistent pattern of low transmission seasons, usually lasting between two and three months, followed by COVID-19 outbreaks, he added.

“We’ve seen this four times,” said Nkengasong. 

A week ago, the African Union launched the Vaccination Bingwa Initative aimed at encouraging young people to get vaccinated.

The initiative seeks to establish a network of COVID-19 vaccination youth champions (bingwa means champion in Swahili) across the continent to accelerate the uptake of coronavirus vaccination in Africa.

Young protesters in Delhi, India take to the streets to demand action against air pollution during a 2019 air pollution emergency.

Nearly ten years of air pollution data for dozens of Indian cities – among the most polluted in the world – was deleted from the latest World Health Organization Air Quality database just before WHO published the report on 4 April 2022, Health Policy Watch has learned. 

The Indian air quality data, spanning the years 2010 to 2019, and including 1,139 data points in all, was collected largely from published government sources, including India’s Central Pollution Control Board, and the government’s SAFAR air quality research network, supplemented by the US State Departments AirNow network, which monitors air quality from missions and embassies around the world.  

The suppressed Indian data is reproduced in full here by Health Policy Watch from the embargoed version of the WHO release, alongside the data of other South-East Asian Region cities and communities.

India is among eight other countries in WHO’s South-East Asia region whose data was originally included in the report.  Others included neighbouring Bangladesh, Nepal, and Sri Lanka, as well as Bhutan, Indonesia, Maldives, Myanmar, and Thailand. 

Except for India, all of the other countries’ data from the region remained intact in the public excel version of the database that was put online by WHO at its 4 April launch

Why is this important?

The omission is significant as the WHO database was for many years regarded as a gold-standard baseline for assessment and comparison of countries’ air quality challenges. While it has been superseded, somewhat, by a range of other open-access and research-based data collection efforts, WHO’s work remains a critical benchmark for national, regional and global analysis of air pollution challenges in different cities and regions. 

Alongside more cutting edge satellite data and other ‘modelled’ data sources, the ground station monitoring data collected by WHO also is a major input to the global bosy’s assessments of air pollution exposures, illness and premature deaths. 

An estimated 4.2 million people die every year from diseases attributable to ambient (outdoor) air pollution levels – with the largest burden in the South East Asia region, according to WHO.  About 7 million people die from combined ambient and household air pollution exposures, with some overlap between the two risk factors.  WHO estimates that in India alone, nearly 1.8 million people die from air pollution every year. 

WHO – No response to queries  

Dr Maria Neira, Director of WHO’s Department of Environment, Climate Change and Health, at a media briefing on the 2022 WHO Air Quality database update.

Health Policy Watch repeatedly sent queries to WHO officials and spokespeople asking why the Indian data had been wiped clean from the 2022 version of the WHO database. WHO initially did not reply. 

However, following publication of this report Thursday, a WHO scientist told Health Policy Watch, “The data for India will be released soon. The data is still going through final checks to ensure accuracy.”  The scientist rejected suggestions that the data had been pulled at the last minute as a result of political pressures – but rather out of an abundance of caution with the sensitive data set.

The WHO trumpeted that its latest WHO Air Quality database was its largest collection of ground station monitoring data ever. And indeed it was. 

The publicly available excel sheet contains new data on average annual particulate concentrations from around 6,000 cities and settlements worldwide – but Indian data is nowhere to be found in the new collection of concentrations of PM10 and PM2.5 – the pollutants most directly linked with a range of cardiovascular, respiratory diseases and cancers, and related premature deaths. 

The 2022 database, the first WHO update since 2018, also included some more limited data on NO2 concentrations for the first time ever – a common pollutant from vehicle emissions that is a precursor to ozone, stunting food production exacerbating asthma and other chronic respiratory diseases.  The embargoed version of the WHO database also reflected new reporting on Indian NO2 data, which also was deleted from the published version.  

WHO global Air Quality map, presented with its 2022 database update. The darkest green areas highlight parts of the world with the highest air pollution levels, but with little granularity to distinguish countries with high levels of pollution, from those with the most dangerous levels, e.g. 15×20 times WHO guideline levels or more.

India’s data – controversial from the beginning of the WHO effort

Pollution in Delhi peaks in late autumn when drifting emissions from crop burning exacerbate the usual urban household, traffic and industrial sources.

India’s data has been a regular feature of the WHO Air Quality database for nearly a decade when the global health agency first started amassing data in order to build a more accurate model of disease and deaths from air pollution – a then poorly-recognized factor in cardiovascular and respiratory diseases as well as cancers. 

The collection of such data was a particularly bold move for the agency at the time.  And it caused a big stir worldwide – particularly in India, which emerged as one of the world’s most polluted countries – overtaking China which had begun making strenuous efforts to clean up its skies. 

Both in private and publicly, Indian air quality officials repudiated WHO’s findings, which placed Indian cities at the top of the global air pollution charts, saying that the WHO assessment provided a distorted view of the state of the country’s air. The Indian officials complained that WHO was overestimating air pollution levels in Delhi, despite the fact that the city faces an air pollution emergency almost every winter as crop waste burning in rural areas to the north drive smoke to the city, combining with Delhi’s already dirty urban sources, transforming the city into a pollution nightmare.   

The government’s objections were often linked to highly technical issues such as: a) the reliance upon one air pollution monitoring station in many Indian cities; b) alleged bias toward data from pollution hot spots where stations are placed; c) bias from stations that don’t operate continuously and; d) a lack of reference to the fact that some of India’s urban pollution is due to dust, rather than human sources. 

Over time, those protests have increasingly sounded hollow as more air quality research was published with similar findings. Meanwhile, India’s own air quality monitoring data was constantly improving revealing a similarly dire picture. Any shortcomings that still exist in Indian data, or reporting about it, can be overcome by careful analysis, experts say. 

 

Real-time air pollution data broadcast in Delhi, during a 2019 air pollution emergency; showing data of government monitoring networks, CPCB, DPCC and SAFAR.

The Indian data included in the 2018 WHO database released four years ago was received in just that light by Indian air quality junkies who combed it for both strengths and gaps. That reflects exactly the kind of transparent debate that is missing from the 2022 release – along with the Indian data itself, of course. 

So if the Indian government had asked WHO to pull the data, it would be particularly hard to understand why now since other reputable global air quality research is now producing similar order-of-magnitude results, year after year. While precise estimates of air pollution levels and peoples’ exposures in different Indian regions and cities might vary across diverse analyses, they tend to reflect the same unhealthy air pollution concentrations across large swathes of northern India, until the present day. 

Other global databases carefully tracking Indian trends 

One such example is the State of Global Air, a report by the Boston-based Health Effects Institute (HEI). HEI also funds air quality research involving Washington University, St. Louis, the University of British Columbia and the University of Washington. Together, those institutions regularly scrape and analyze publicly available Indian monitoring data from official sites. In combination with NASA satellite data and other data, they, too, produce estimates of average annual PM2.5 concentrations and from those inputs, model the levels of “population exposure” to air pollution in India, and worldwide.   

According to some of those recent findings, further distilled by an Indian analysis, and portrayed graphically here, nearly a quarter of India’s population was exposed to annual average PM2.5 concentrations ranging from 80 micrograms/meter3 (µg/m3) or more in 2020 . This is 16 or more times higher than the WHO guideline level of 5 µg/m3 for PM2.5.  That guideline limit was tightened by WHO in 2021 in the face of mounting evidence about the health impacts of particulate air pollution, even at comparatively low concentrations.  

Indian analysis of the proportion of a) people exposed and b) land area covered by air pollution at various levels in 2020, based on data extracted from a global database distributed by Washington University, St. Louis USA. (Source: urbanemissions.info)

Air pollution worsened over the past two decades 

India air quality analysis (year 2000), based on data extracted from a global database by Washington University in St. Louis, USA. (source urbanemissions.info)

Looking back further, however, India’s air pollution has worsened significantly over the past two decades.  A comparison of the same mapping from 2000 and 2020 highlights that trend, showing a much wider belt of northern India etched in the dark browns and orange of excessive pollution levels, as compared to the green shades of two decades ago.  

Annual average air pollution exposures appeared to peak in 2014 then had a slight, gradual decline, stagnating at a high level of around 80 µg/m3 for PM2.5, suggests data from the State of Global Air report series. 

Population-weighted exposure to polluted air in India over time. (State of Global Air, Health Effects Institute)

WHO data on Delhi – from the embargoed WHO data set never released – reflects similar trends and fluctuations – even if it is urban, not national, data – and framed somewhat differently in technical terms.

According to the WHO data compilation, Delhi’s PM2.5 levels peaked as well around 2014, and then declined somewhat, levelling off recently to concentrations of about 105 µg/m3  – still some 21 times higher than recommended WHO guideline levels of 5 µg/m3. But a deeper analysis by WHO would be needed to be performed to further gauge trends nationally or regionally over time. Needless to say, with the most recent India data missing altogether, that kind of trend analysis hasn’t been done in WHO’s latest Status Report.  

Delhi air pollution data (PM2.5) from 2010-2019, which was deleted from the WHO’s final, published version of its 2022 Air Quality database. It shows a sharp rise in average annual levels in 2014, which then declined and steadied at concentrations still 26 times above new WHO guideline levels.

CPCB  officials  say data is freely available on website, no reply from SAFAR  

Health Policy Watch reached out to several Indian government air quality officials for explanations as to why India’s data had disappeared from the final version of the 2020 WHO air quality database. 

Calls to Dr Prashant Gargava, Member Secretary of the Central Pollution Control Board (CPCB), India’s statutory body, went unanswered. 

But two other senior CPCB officials said in separate phone interviews that updated CPCB data is freely available on their website for the general public – and denied there had been any effort to censor WHO’s report. 

“As far as I know, the WHO has not asked us for any data. They are welcome to take it from the website – anyone can do that,” one official told our India correspondent. 

“We have data from our manual as well as our CAQM (continuous air quality monitoring) stations on our website – anyone can take that data – they just have to mention the data source and acknowledge it,” the official who directly supervises this data said.   

An independent Indian air pollution expert interviewed by Health Policy Watch, also confirmed that since the Indian air quality data is publicly available from the official, Central Pollution Control Board, database, the statutory Air Quality monitoring body in India – WHO certainly shouldn’t censor itself over use.  

“Technically CPCB is posting the data online and it is supposed to be public by default for anyone to use, with due credit,” the data scientist  told Health Policy Watch, “Then why not just use it, and not ask for another permission to use it.”   

Other major Indian data sources: SAFAR and the US State Department’s ‘AirNow’

SAFAR India, a government air quality research and monitoring network with an extensive monitoring system in Delhi

WHO’s suppressed Indian data set also drew upon data from SAFAR-India, a parallel research network operated by the Indian Ministry of Earth Sciences. 

SAFAR, the “System of Air Quality and Weather Forecasting And Research” is an internationally recognized network that collects data from 11 monitoring stations in Delhi, as well as individual stations in 11 other Indian cities. It’s network includes academic, and meteorological research institutions, as well as some municipal authorities. 

SAFAR also provides real-time air quality forecasting and alerts, based on an Air Quality Index, important for air pollution emergencies. Its reporting is particularly important for Delhi, which suffers some of the worst pollution peaks in the country almost every winter, and along with that, the need to make decisions about drastic public health measures, from mask distribution, to work stoppages and school closures.   

A leading air pollution official at SAFAR contacted by Health Policy Watch about the removal of the Indian data from the 2022 WHO database, also did not respond to emailed requests for clarifications, as of the time of this publication. 

Even so, insofar as authoritative Indian data is plentiful, current and public, there should be no problem with WHO using it freely.

The Indian data scientist interviewed by Health Policy Watch stated: “I think WHO should scrape it [the data], or use a group scraping the data, to make their own current averages and publish. This is public information, though it is a little difficult to access data in bulk from the CPCB site, some groups have already put in their time to make it useful.

“My personal opinion (and that of some others) is that when we get stuck in this circle of permissions to even publish what is already public, it makes policy dialogue very difficult, leading to second-guessing to do the right thing, even as simple a task as public awareness of health impacts of air pollution.”

WHO – a scientific or member state body? 

A World Health Assembly committee meeting, 2018.  WHO’s findings and recommendations are supposed to be science-based, but member states constantly lobby for influence, particularly to shape the outcomes of unflattering or unfavourable reports and recommendations.

But the pressures WHO faces as a science body, under the constant scrutiny of its member states, tends to complicate its research. In fact, whenever potentially unflattering data lurks, the WHO tends to walk tiptoe around the sensitivities of member states. 

This has been highlighted during the COVID-19 pandemic in WHO’s public statements and relation to member states from China to Italy. In the case of the latter, WHO withdrew from a 2020 report on Italy’s pandemic response, An unprecedented challenge, just a few hours after it was published. Although the official narrative was that the account was deleted was due to “errors”, the report’s chief coordinator, who has since left the WHO, attributed the report’s withdrawal to intense political pressure from the government of Italy and a leading WHO official affiliated with the government, who had found certain findings unflattering.

A pattern of much-delayed reports in WHO’s Disease Outbreak News about new outbreak threats can also likely be traced to excessive concerns with member states’ sensitivities. 

There was a three-month delay in WHO’s publication about the recent wild polio outbreak in Malawi, which occurred in November 2021, but only was reported by WHO in late February 2022, shortly before it launched a five-nation vaccination campaign. A July 2021 Zika outbreak in India’s Kerala and Maharashtra states was only reported by WHO in October 2021, a full three months after the outbreak came to light – with considerable local media coverage.    

In the case of the WHO air quality database, traditionally, data had to be reviewed by countries prior to WHO’s publication. More recently, an online template for government authorities to enter their own data manually is now available on the WHO website. That, WHO says, has become one of the “primary sources of data” potentially also simplifying the official approval process. 

“The primary sources of data were official reports of countries sent to WHO upon request, official national and subnational reports and national and subnational websites that contain measurements of PM10 or PM2.5 and ground measurements compiled in the framework of the Global Burden of Disease project,” state WHO acknowledgements. 

“Measurements reported by the following regional networks were also used: Clean Air for Asia, the Air quality e-reporting database of the European Environment Agency for Europe and the AirNow Programme from the United States embassies and consulates. If such official data were not available, values from peer-reviewed journals were used.”

Missing Indian data went unnoticed in media reports   

Despite the widespread attention that the WHO Air Quality database updates typically receives, major media reporting of the 2022 Air Quality database update, entirely missed the fact that the Indian data had been suppressed from the update, both in India and media reports published abroad

Health Policy Watch also reported on the 4 April WHO database launch, with reference to various Indian cities as global pollution hotspots. 

In our report, we explicitly referred to Indian urban data contained in the embargoed database – which we had downloaded from the embargoed report ahead of publication without realizing that the same data had been deleted from the actual, published database that went online that day. 

South-East Asia, Africa and Middle East are World’s Air Pollution Hot Spots in WHO’s Largest-Ever Data Release 

Only a few days later, did it become apparent in an interview with a global air quality expert, that all of the Indian data contained in the embargoed version of the report had been removed from the final report. 

Indian data removed just days before launch

Insofar as the embargoed version of the WHO database is dated 31 March 2022, it’s clear that the Indian data was removed at the very last minute. For those who look diligently, however, historical Indian data from previous years can still, however, be found online in previous versions of the Air Quality database, at least for now.  For instance, at the time of this publication, the following historical data for India could be found in WHO’s:

  • 2011 database, the first version of WHO’s public collection efforts, has data for 31 Indian cities, dating from 2008; 
  • 2014 database, which had data from 123 Indian cities, including multiple stations in some cities, dating from 2010-2012;
  • 2016 database has average annual data from 131 Indian cities, including multiple stations in some cities, all dating from 2012;
  • 2018 database update, in contrast, has annual averages from only 31 Indian cities, including multiple stations in many cities, dating from 2016;  

Heavy reliance on US State Department’s Air Now database for new data on major Indian cities

Real-time data for Delhi, India as of 13 April, collected by the US State Department’s AirNow initiative.

Along with data from CPCB and SAFAR, a third source for Indian data in the embargoed database version was the US State Department’s “AirNow” monitoring system.

AirNow covers cities in the United States, as well as internationally, in sites where the US has a diplomatic presence. Over the past decade, air quality monitoring systems were established in embassy and mission buildings, as a measure to protect the health of diplomatic staff. As real-time continous data is published online, the system serves the secondary function of awareness-raising about air pollution in local communities.

Among the 100 new data points cited from  2017-2019 in the embargoed report, analyzed by Health Policy Watch, values for most of India’s largest cities are attributed to AirNow. For instance, major cities with annual average PM10 data from 2019, attributed to AirNow, include:

Those concentrations are 5 to 11 times above the WHO guideline of 15 µg/m3  for PM10.  

For cities with PM2.5 data, AirNow is also cited as the main source. It includes Delhi’s PM2.5 annual average of 105 µg/m3 (2019) which ranked it as the most polluted city in India for that year – 25 times above the WHO guidelines of 5 µg/m3. Other cities with data sourced from AirNow, reported concentrations 8-12 times above the WHO guideline levels for PM2.5, including: 

Outside of large cities, however, the 2017-2019 data for other Indian cities was attributed to CPCB or SAFAR.   

Passive data collection – versus ‘data scraping’ 

One noteworthy feature of recent WHO air quality reporting is the fact that the expanding Air Quality database is soliciting and receiving more active contributions by the countries themselves via the online template

“The WHO global ambient air quality database is continuously being updated. If you are an official air quality data provider at either the country or city level, please use this template to submit the data to WHO,” states WHO on its air quality theme pages.

While certainly that helps engage countries more actively in the air pollution data collection process, the question is what happens when officials are reluctant to share their data at all?  

It’s possible that in the absence of an active contribution from the Indian government, WHO scraped data available from AirNow and the CPCB for key Indian locations – and then discarded it at the last minute after India objected. But without clear answers from WHO, that remains speculation. 

Other countries’ air quality data is also outdated or missing    

Israel maintains a sophisticated air pollution monitoring system, with public reporting of real-time data and annual averages from dozens of points within its recognized pre-1967 borders. But the latest Israeli data points in the WHO database are seven years old.

Those are not the only questions about the database, however, that remain unanswered.

While this year’s WHO Global Air Quality database update can indeed boast the largest number data points ever, coverage by region remains highly inconsistent, as WHO’s own maps reveal. 

In some key regions, broad data networks such as the European Environment Agency and Clean Air Asia, also capture lots of data for WHO from countries uninterested or unable to report for themselves.  

But such networks do not extend everywhere. And so, whether as a result of barriers of language, technical incompetence, or pure indifference, cities and even whole countries with data can fall entirely through the cracks. 

Israel, a high-income country considered to be part of WHO’s European Region, has had no new data entries recorded in the WHO database since 2015. That is despite the fact that Israel has a sophisticated air quality network, publishing real time air quality data and annual average PM2.5 values for dozens of cities and locations within its pre-1967 borders. However, that database is in Hebrew and WHO’s data searches are limited to English, French, Spanish and Portuguese, as described in its Status Report on the 2020 update

A spot check by Health Policy Watch also found cities in the United States had outdated data. For example, Columbus, Ohio, a major industrial city in the midwest, has not reported an updated value for average annual PM2.5 concentrations since 2011. 

New African data – laudable but still loaded with flaws 

Accra, Ghana, is one of Africa’s few cities monitoring air pollution – but its last publicly reported measurement dates from 2015.

The newest version of the WHO database also is noteworthy for its growing list entries of data from the WHO African Region. 

This year’s update includes nearly 50 data points across more than 10 major African countries, including Kenya, Ghana, Nigeria, Cameroon, Uganda, Senegal – as well as South Africa, which has the largest and most well-established network including some 140 monitoring stations.  

However, even the African data represented here often appears dated and patchy, yet many countries have rapidly growing cities that desperately need more consistent and transparent reporting on air quality. 

Accra in Ghana is one such example.  Home of one of the largest e-waste facilities in the world, it suffers from considerable air pollution from the incineration of plastics and other hazardous materials. In 2015, the city publicly reported its air pollution data for the first time ever – revealing an annual average PM2.5 value of 55 µg/m3 – 11 times more than the WHO Guideline levels. That measurement is now seven years old. Nothing has been reported since. 

And that is despite intensive efforts to strengthen the city’s air quality monitoring efforts through a WHO-led Urban Health Initiative, co-sponsored by UNEP and a joint US-World Bank initiative, which saw the installation of new air quality monitoring equipment in Accra in October 2021.    

Nairobi’s single data point in the WHO database is a value of 5.91µg/m3 of PM 2.5 for the year 2018. 

That value, provided by the US State Department’s AirNow monitoring, may be unrepresentative of the city as a whole if it is drawn from monitors at the US Embassy itself. The Embassy is located in a posh neighborhood on the northern edge of Nairobi just past the famed Karura Forest, which would act as a natural filter for air pollutants drifting from the center city. 

Other available real-time data, as well as peer-reviewed studies of Nairobi’s air quality also suggest much higher levels for the downtown area. But the WHO data doesn’t yet consider new, and increasingly robust methods of low-cost air quality monitoring being rolled out in low-income cities such as Nairobi.  

Data shortcomings: mix of politics and resource shortages 

Taken together, the gaps and shortcomings described here are a complex mix of objective circumstances (e.g. Africa’s air quality monitoring network was largely non-existent only a few years ago); human resource shortages, and long-ingrained institutional and political constraints. 

WHO insiders point to the fact that WHO’s core air quality database team is led by a single staff scientist. That effort is indeed supported by a wider circle of consultants and advisors, including known global experts such as Michael Brauer, at the University of British Columbia, and Gavin Shaddick, of the University of Exeter.  But collaborations with busy professionals accountable to their own institutions can only go so far.  

So while other global air quality monitoring initiatives now boast flashy websites with interactive maps, charts and graphics, that ease public understanding and highlight trends, WHO’s database remains a single PDF file and flat excel sheet download.  That alone makes the job of sorting and assessing values across cities, countries, regions, and over time onerous, to say the least. 

In its global database effort, WHO largely goes it alone. But acting alone, WHO also may be underpowered for the massive task that it tries to fulfil.  

Even so, until WHO and the Indian government reinstate the India data, as well as explaining more transparently why it went ‘missing-in-action’, dialogue about a way forward that is more robust, accessible, up-to-date, and inclusive, of all countries’ data would be difficult.  

Removal was unplanned and occurred at the last minute

The gauge on the WHO-led BreatheLife campaign site reveals some of the recent India data deleted from the technical database. Here, results of a search for Delhi.

But whatever the drivers, it’s clear is that the removal of the Indian data was unplanned and came only at the very last minute.

For instance, at least some of the new Indian data points suppressed in the technical report can be called up on the interactive search tool of the BreatheLife campaign – a joint awareness-raising effort of WHO, the United Nations Environment Programme’s Climate and Clean Air Coalition (CCAC). A search for Delhi, Chennai, Kolkata and Mumbai showed the gauge arrow responding with the same 2019 value for PM2.5 (105µg/m3that had been deleted from the technical data base.

In addition, the online WHO Status Report, the technical report that accompanied the 4 April database launch, also displays the Indian data points for PM10 and PM2.5 in its global map of monitoring stations from which data was collected. 

That technical summary, still marked with the big bold words DRAFT on its cover and inside pages, even calls out the Indian data monitoring effort in a caption that states: “More ground measurements are generally found in high- and middle-income countries, in China, Europe, India and North America.”

Ultimately, the removal of the India data was not only hasty but awkward for the entire WHO database effort; the end of the story can only be written by WHO and India’s official authorities.  

_________________________________________________________________________

Elaine Ruth Fletcher is the editor-in-chief of Health Policy Watch. From 2003- to 2018 she was a technical officer and editor at the World Health Organization, engaged mostly in WHO’s air pollution and urban health work – including co-founding the BreatheLife campaign dedicated to awareness raising of the health and climate impacts of air pollution. She is the co-author and/or editor of over two dozen WHO reports and peer reviewed journal articles on air pollution, urban health and other environmental health themes. 

Jyoti Pande Lavakare is a core contributor to Health Policy Watch from Delhi. She is the author of the recently published grief memoir on the human cost of air pollution titled “Breathing Here is Injurious to Your Health”, and a long time contributor to Indian and global media on air pollution themes. She is also co-founder of the Indian NGO, Care for Air.

-Updated at 18:50 CEST 14. April 2022 with initial reply from the World Health Organization.

Image Credits: DYFI Delhi Twitter, Flickr, www.aqicn.org, urbanemissions.info, urbanemissions.info, State of Global Air/Health Effects Institute, Embargoed version of the WHO air quality data base, WHO/A. Kari, WHO Ambient Air Quality Update 2022 Status Report .

IFPMA Director General Thomas Cueni (foreground) with moderator Claire Doole and Albert Bourla, David Ricks and Bill Anderson on screen.

Pharmaceutical giants have questioned why a waiver on intellectual property (IP) rights for COVID-19 vaccines is still on the table when they are battling to find markets for their vaccines amid order cancellations – including from the Africa Centre for Disease Control. 

“I’m stunned that the proposed IP waiver is still being debated while supplies of vaccines are far outstripping demand and some factories have been put to a halt because of missing orders,” Thomas Cueni, Director General of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) told a media briefing on Wednesday.

With almost a billion vaccines now being produced every month, countries’ lack of capacity to vaccinate is now the main barrier to stopping COVID-19, added Cueni.

In the first quarter of the year 13.7 billion vaccine doses were delivered and 11 billion doses administered, said Cueni.

“Now orders are slowing down. Countries as well as organisations such as Africa CDC, are not only asking for orders to be delayed but are cancelling them,” added Cueni.

“Leading voices are still calling out vaccine scarcity. I do understand the concern. Vaccines are not reaching all those who need them. But the cause is no longer the lack of supplies. It’s scarcity of vaccination, which is due to the lack of country readiness, absorption capacity and the lack of resources needed to get the vaccines into arms.”

Countries’ lack of capacity

Pfizer CEO Dr Albert Bourla also weighed in on country capacity, saying that the US government was offering 200 million free doses to the poorest countries of the world but they lacked the capacity to administer the vaccines.

“The problem is not if there is availability or access to pricing. The problem is that the infrastructure of these countries is very poor, so they cannot absorb them. They cannot run a vaccination campaign,” said Bourla.

Bourla added that one of the pandemic’s key lessons was that more attention should have been paid to preparing countries to vaccinate people.

He also described any move to remove IP on vaccines as “insane”, while Roche CEO Bill Anderson described it as “unproductive”.

Eli Lilly CEO David Ricks warned that pharmaceutical companies and investors would “never have invested” in trying to develop COVID-19 vaccines “if there was not the promise of IP”.

“The next investments on the unknown technology which we can repurpose for the next pandemic won’t be made if investors believe that IP will be undermined,” warned Ricks.

“What is a patent? It’s a promise to disclose our inventions in return for a period of exclusivity,” added Ricks. “You’ll get much less disclosure about inventions actually as a result of an IP waiver. There’ll be a strong incentive to retain know-how, retain the recipes for what we do, much like you see in some other industries.”

Collaboration successes

Bourla said one of the best aspects of the pandemic had been the collaborations between different the industry partners, where competitors worked together, as we as public-private collaboration, particularly with regulators. 

He commended particularly the US Food and Drug Administration, the European Medicines Agency and the Canadian, Israeli and Japanese regulators for their speedy reviews of industry data.

“What did not help was the politicisation – if you take a vaccine or not, or wear a mask or not. Tthat created tremendous damage to the global health,” said Bourla.

At the IFPMA briefing (clockwise): Pfizer CEO Albert Bourla, IFPMA Director General Thomas Cueni and moderator Claire Doole, Roche CEO Bill Anderson and Eli Lilly CEO David Ricks

Future COVID vaccines

The IFPMA noted that there was “increasing acceptance that society will have to live with COVID-19”, and that continued innovation remains essential to expand on the 10 vaccines that have so far received WHO Emergency Use Listing approval and the 18 different treatments that have been approved in the UK, USA, and EU. 

Bourla said that Pfizer and Moderna were working on “multivariant” vaccines but this was “very challenging”, as was developing a COVID-19 vaccine that offered robust protection for at least a year.

He hoped this would be ready for testing in the third quarter of the year.